The UK government wants to increase the production of medicines in orbit around the Earth. Its new initiative aims to chart a clearer path to safely bring drugs made in space to market. The Civil Aviation Authority, the Medicines and Healthcare products Regulatory Agency, the Innovation Regulatory Authority and the UK Space Agency have agreed to work together to ensure a supportive regulatory environment for space, biopharmaceutical and pharmaceutical companies. The low-gravity environment of space allows for more precise formulation of drugs, especially biologics and protein-based drugs such as monoclonal antibodies, vaccines, and insulin. Microgravity conditions improve drug solubility, purity, crystallization, and stability, promote more efficient delivery, and can reduce manufacturing risk and cost. The British Space Agency has provided funding for three on-orbit manufacturing studies, including £250,000 to London.